指南与共识前列腺癌男科与性医学

专家共识建议:接受聚ADP核糖聚合酶抑制剂联合新型内分泌治疗的转移性前列腺癌患者治疗中出现不良事件的管理

Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy.
指南 / 共识 · Eur Urol Oncol · 2024-06-12

该专家共识采用RAND/加州大学洛杉矶分校改良Delphi法,由12名专家针对419个患者场景评估聚ADP核糖聚合酶抑制剂联合新型内分泌治疗相关不良事件的管理策略;第二轮评分形成推荐,包括轻度不良事件继续治疗并对症处理,中度疲劳或重度恶心/呕吐或血红蛋白7.1-8.0 g/dl伴贫血症状时暂停治疗并在缓解后减量重启。

要点

  • 轻度不良事件建议继续治疗并对症处理。
  • 中度疲劳推荐非药物治疗、暂停治疗,缓解后减量重启。
  • 重度恶心或任何程度呕吐对症治疗失败时暂停治疗,缓解后减量重启。

核心结论

  • 该专家共识可为接受聚ADP核糖聚合酶抑制剂联合新型内分泌治疗的转移性前列腺癌患者的不良事件管理提供支持。

研究设计与样本

  • 采用RAND/加州大学洛杉矶分校改良Delphi法,由12名专家(7名肿瘤内科医生、1名高级执业注册护士、3名泌尿外科医生和1名患者权益倡导者)对419个患者场景独立评分,并于2023年3月会议讨论后重复评分。

主要发现

  • 第一轮与第二轮评分之间,专家意见不一致率从41%降至21%,且对所有不良事件均达成至少一种管理策略的共识。

关键数值与推荐

  • 对于轻度不良事件,继续治疗并对症处理。
  • 对于中度疲劳,推荐非药物治疗,暂停治疗,待症状缓解后减量重启。
  • 对于重度恶心或任何程度呕吐且对症治疗失败,暂停治疗,待症状缓解后减量重启。
  • 对于血红蛋白7.1-8.0 g/dl且伴有贫血症状,暂停治疗,红细胞输注后减量重启。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Recent clinical trials have shown improvement in progression-free survival in men with metastatic prostate cancer (mPC) treated with combination poly-ADP ribose polymerase (PARP) inhibitors (PARPi) and novel hormonal therapy (NHT). Regulatory bodies in the USA, Canada, Europe, and Japan have recently approved this combination therapy for mPC. Common adverse events (AEs) include fatigue, nausea and vomiting, and anemia. Nuanced AE management guidance for these combinations is lacking. The panel objective was to develop expert consensus on AE management in patients with mPC treated with the combination PARPi + NHT. METHODS: The RAND/University of California Los Angeles modified Delphi Panel method was used. AEs were defined using the Common Terminology Criteria for Adverse Events. Twelve experts (seven medical oncologists, one advanced practice registered nurse, three urologists, and one patient advocate) reviewed the relevant literature; independently rated initial AE management options for the agent suspected of causing the AE for 419 patient scenarios on a 1-9 scale; discussed areas of agreement (AoAs) and disagreement (AoDs) at a March 2023 meeting; and repeated these ratings following the meeting. Second-round ratings formed the basis of guidelines. KEY FINDINGS AND LIMITATIONS: AoDs decreased from 41% to 21% between the first and second round ratings, with agreement on at least one management strategy for every AE. AoAs included the following: (1) continue therapy with symptomatic treatment for patients with mild AEs; (2) for moderate fatigue, recommend nonpharmacologic treatment, hold treatment temporarily, and restart at a reduced dose when symptoms resolve; (3) for severe nausea or any degree of vomiting where symptomatic treatment fails, hold treatment temporarily and restart at a reduced dose when symptoms resolve; and (4) for hemoglobin 7.1-8.0 g/dl and symptoms of anemia, hold treatment temporarily and restart at a reduced dose after red blood cell transfusion. CONCLUSIONS AND CLINICAL IMPLICATIONS: This expert guidance can support management of AEs in patients with mPC receiving combination PARPi + NHT therapy. PATIENT SUMMARY: A panel of experts developed guidelines for adverse event (AE) management in patients with metastatic prostate cancer treated with a combination of poly-ADP ribose polymerase inhibitors and novel hormonal therapy. For mild AEs, continuation of cancer therapy along with symptomatic treatment is recommended. For moderate or severe AEs, cancer therapy should be stopped temporarily and restarted at the same or a reduced dose when AE resolves.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Shore ND, Broder MS, Barata PC, et al. Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy. Eur Urol Oncol. 2024. PMID: 38866640. doi:10.1016/j.euo.2024.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。